<DOC>
	<DOCNO>NCT00642902</DOCNO>
	<brief_summary>To evaluate safety tolerability atacicept explore atacicept reduce central nervous system inflammation subject relapse multiple sclerosis ( RMS ) assess frequent magnetic resonance imaging ( MRI ) . This study randomise . Study medication administer via subcutaneous ( skin ) injection .</brief_summary>
	<brief_title>A Phase 2 Study Atacicept Subjects With Relapsing Multiple Sclerosis ( ATAMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis RMS ( per McDonald criterion , 2005 ) Other protocoldefined inclusion criterion could apply . Have primary progressive multiple sclerosis ( MS ) Have secondary progressive MS without superimpose relapse Relevant cardiac , hepatic renal disease specify protocol Pretreatment immunosuppressant immunomodulating drug specify protocol Clinical significant abnormality blood cell count immunoglobulin level specify protocol Clinical significant acute chronic infection specify protocol Other protocoldefined exclusion criterion could apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Atacicept</keyword>
</DOC>